Vaxcyte Names CMO and CLO, Pulls Forward VAX-31 OPUS-1 Data Readout to End of October
PCVX sits 96% above its 52-week low of $30.81.
Summary
Vaxcyte appointed a new Chief Medical Officer and Chief Legal Officer and narrowed its VAX-31 OPUS-1 topline data readout guidance to the end of October 2026.
Key Events · Executive and Board Changes · PCVX
-
CMO and CLO Appointments
Luis Jodar, Ph.D. (former Pfizer CMO for Vaccines and Infectious Diseases) joins as Chief Medical Officer; David McAvoy, J.D. (former Teva CLO) joins as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.
-
OPUS-1 Data Readout Narrowed to October
Topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial is now expected by the end of October 2026, narrowing prior Q4 2026 guidance.
-
Leadership Bench Ahead of BLA
The appointments deepen the leadership team as Vaxcyte approaches the OPUS-1 readout and prepares for the planned Biologics License Application submission and potential launch of VAX-31.
-
OPUS Program Milestones
OPUS-2 and OPUS-3 Phase 3 safety, tolerability, and immunogenicity data are expected in the first half of 2027; the OPUS program has dosed 6,191 adults, approximately 3,500 of whom received VAX-31.
Analysis · PCVX · Life Sciences
Vaxcyte appointed Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer, and narrowed its guidance for the VAX-31 adult Phase 3 OPUS-1 topline data readout to the end of October 2026, from the previously communicated fourth quarter. The appointments bring deep pneumococcal conjugate vaccine and biopharma legal experience ahead of the pivotal readout and planned BLA submission. The narrowed timeline reduces uncertainty around the company's most important near-term catalyst, and the CMO hire in particular signals operational readiness for the data and potential commercialization.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCVX was trading at $60.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $30.81 to $65.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.